Featuring market attractiveness scoring, total addressable market sizing, company benchmarking matrices, interactive Excel dashboards, deeper supply chain intelligence, emerging startup tracking, and granular product-level insights, The Business Research Company’s 2026 market reports are built to deliver research that is both more actionable and more strategically valuable.
Genomic Biomarker Market Revenue Growth On Track For A 17.5% CAGR Through 2030
The genomic biomarker market has experienced substantial growth in recent years. This market is projected to expand from $9.9 billion in 2025 to reach $11.67 billion by 2026, demonstrating a compound annual growth rate (CAGR) of 17.8%. Factors contributing to its historical growth include greater investment in genomic investigations, wider scope of biomarker studies concentrating on oncology, enhanced accessibility of next-generation sequencing methods, increasing partnerships between diagnostic firms and pharmaceutical enterprises, and the pioneering embrace of tailored medicine strategies.
The genomic biomarker market is set to undergo significant expansion in the coming years. It is projected to achieve a size of $22.23 billion in 2030, exhibiting a compound annual growth rate (CAGR) of 17.5%. The projected increase in this period can be attributed to factors like the escalating demand for precision medicine therapies, the expanding utilization of biomarkers in drug development, the wider adoption of companion diagnostics, an increased emphasis on detecting diseases early, and strengthened regulatory backing for biomarker-based approvals. Key trends anticipated during the forecast period include the rising acceptance of predictive genomic biomarkers, an increase in pharmacogenomic testing, the growing integration of genomic data into clinical decision-making, the broadening scope of biomarker-based oncology diagnostics, and a sharpened focus on clinical validation standards.
Get A Free Sample Report With In-Depth Market Insights:
Genomic Biomarker Market Expansion Drivers: What’s Shaping Future Growth?
The expanding occurrence of chronic illnesses is anticipated to boost the development of the genomic biomarker market in the future. Chronic ailments represent enduring health states that persist for extended periods and frequently advance gradually. The growing frequency of chronic diseases stems from an aging global populace and escalating instances of lifestyle-associated issues like obesity and diabetes. Through the identification of genetic predispositions and the customization of interventions, genomic biomarkers facilitate early diagnosis and individualized preventive approaches for chronic illnesses. Such a forward-thinking method aids in lowering the incidence by focusing on susceptible individuals prior to the emergence of the disease. As an illustration, in September 2023, the World Health Organization (WHO), a Switzerland-based intergovernmental body, reported that 41 million global deaths occur annually, constituting 74% of all deaths linked to chronic diseases. These figures encompass 17.9 million fatalities from cardiovascular diseases, 9.3 million from cancer, 4.1 million from chronic respiratory diseases, and 2.0 million from diabetes. Consequently, the rising incidence of chronic diseases fuels the expansion of genomic biomarkers.
Genomic Biomarker Market Segment Outlook: Which Categories Are Growing Fastest?
The genomic biomarker market covered in this report is segmented –
1) By Type: Predictive Biomarkers, Prognostic Biomarkers
2) By Disease Indication: Oncology, Cardiovascular Diseases, Neurological Diseases, Renal Disorders, Other Disease Indications
3) By Validation: Analytical Validation, Clinical Validation, Clinical Utility
4) By End-User: Hospitals, Diagnostic Centers, Research Laboratories, Other End Users
Subsegments:
1) By Predictive Biomarkers: Genetic Biomarkers For Disease Susceptibility, Pharmacogenomic Biomarkers For Drug Response, Early Detection Biomarkers For Disease Prediction, Biomarkers For Treatment Response Prediction
2) By Prognostic Biomarkers: Biomarkers For Disease Progression, Biomarkers For Outcome Prediction, Survival And Recurrence Biomarkers, Biomarkers For Treatment Efficacy And Prognosis
Genomic Biomarker Market Strategic Trends: What Defines The Next Growth Phase?
Major companies operating in the genomic biomarker market are concentrating on creating sophisticated products, such as advanced liquid biopsy assays, to enable thorough genomic profiling of solid tumors. A liquid biopsy assay serves as a diagnostic test that examines genetic material, typically circulating tumor DNA (ctDNA), obtained from a blood sample to identify and track cancer. Pinpointing genomic biomarkers can yield information about specific mutations, gene expression profiles, or other genetic modifications associated with cancer. For example, in November 2023, Illumina Inc., a US-based biotechnology company, introduced an advanced liquid biopsy assay, the TruSight Oncology 500 ctDNA v2 (TSO 500 ctDNA v2), designed for comprehensive genomic profiling of solid tumors. This assay offers improved analytical sensitivity by detecting low-frequency variants with just 20 ng of cell-free DNA, a reduction from the prior 30 ng. It provides results in under four days, significantly expediting genomic profiling compared to conventional techniques. The optimized workflow and forthcoming automation are expected to simplify lab integration and enhance efficiency.
Genomic Biomarker Market Leading Companies And Competitive Benchmarking
Major companies operating in the genomic biomarker market are Pfizer Inc., Roche Diagnostics, Thermo Fisher Scientific Inc., Merck KGaA, Eurofins Scientific SE, Agilent Technologies Inc., Illumina Inc., PerkinElmer Inc., Beckman Coulter Inc., Bio-Rad Laboratories Inc., Foundation Medicine Inc., QIAGEN N.V., Almac Group Ltd., Myriad Genetics Inc., Invitae Inc., Guardant Health Inc., Novogene Inc., Twist Bioscience Corp., NanoString Technologies Inc., Quanterix Corp., Personalis Inc., GENEWIZ Inc., Agena Bioscience Inc., Creative Diagnostics Ltd., OncoDNA SA, Genome Life Sciences Ltd., Epigenomics AG.
View The Full Genomic Biomarker Market Report:
Genomic Biomarker Market Geographic Spread And Regional Opportunities
North America was the largest region in the genomic biomarker market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the genomic biomarker market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.
Reach Out To Our Team:
The Business Research Company: https://www.thebusinessresearchcompany.com/
Americas: +1 310-496-7795
Asia: +44 7882 955267 & +91 8897263534
Europe: +44 7882 955267
Email us at: marketing@tbrc.info
Follow us on:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ
Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model
